GLSI

$16.38-$0.54 (-3.19%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$248.4M

15M shares

52-week range

$7.78 – $34.10

33% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-24.34

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-1.39	$-1.47–$-1.29	—	2
2027	$9M	—	$-1.17	$-1.17–$-1.17	—	1
2028	$140M	+1500.0%	$3.98	$3.98–$3.98	4.1×	1
2029	$311M	+121.9%	$9.90	$9.90–$9.90	1.7×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.33	$-0.27	+18.2%
2026-06-03	$-0.33	$-0.39	-18.2%
2026-03-31	$-0.32	$-0.32	+0.0%
2025-11-14	$-0.30	$-0.30	+0.0%
2025-08-14	$-0.24	$-0.30	-25.0%
2025-05-20	$-0.24	$-0.25	-4.2%
2025-04-15	$-0.21	$-0.61	-190.5%
2024-11-14	$-0.21

DCF fair valuemodel estimate

Intrinsic value

$0.13

Price

$16.38

Implied downside

-99%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GLSIGreenwich LifeSciences, Inc.	$16.38	-3.19%	$240M	—
AGENAgenus Inc.	$7.00	+1.45%	$291M	—
ATOSAtossa Therapeutics, Inc.	$2.56	+8.94%	$26M	—
CGTXCognition Therapeutics, Inc.	$1.04	+0.00%	$93M	—
HURATuHURA Biosciences, Inc.	$2.30	-1.71%

Greenwich LifeSciences, Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

www.greenwichlifesciences.com

Employees: 13
IPO / List date: Sep 25, 2020
HQ: STAFFORD, TX

Held by traders on TradeandTell

No one on the platform currently holds GLSI.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2025-09-30	38,400	$382.1K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2014-10-16	2-for-1

Recent trades on TradeandTell

No one on the platform has traded GLSI yet.

$GLSI chatter on StockTwits

peacewealth7447@peacewealth74477h
$GLSI How much cash do they have? Is there a chance of dilution?
View on StockTwits ↗
Alians Brenner@skiddy58h
$GLSI
View on StockTwits ↗
Stock_profit_03@Stock_profit_03Bullish8h
$GLSI institutions loading. Are you?
View on StockTwits ↗
peacewealth7447@peacewealth74478h
$GLSI I'm new here. When will the trial be over?
View on StockTwits ↗
Stock_profit_03@Stock_profit_03Bullish9h
$GLSI Northern Trust Corp reports 6.79% increase in ownership of GLSI / Greenwich LifeSciences, Inc. On August 13, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 80,228 shares of Greenwich LifeSciences, Inc. (US:GLSI) valued at $1,882,149 USD as of June 30, 2026. The entity filed a previous 13F-HR on May 14, 2026 disclosing 75,125 shares of Greenwich LifeSciences, Inc.. This represents a change in shares of 6.79% during the quarter. The current value of the position is $1,316,541 USD.
View on StockTwits ↗
Stock_profit_03@Stock_profit_03Bullish9h
$GLSI Morgan Stanley reports 45.66% increase in ownership of GLSI / Greenwich LifeSciences, Inc. On August 13, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 43,447 shares of Greenwich LifeSciences, Inc. (US:GLSI) valued at $1,019,267 USD as of June 30, 2026. The entity filed a previous 13F-HR on May 15, 2026 disclosing 29,827 shares of Greenwich LifeSciences, Inc.. This represents a change in shares of 45.66% during the quarter. The current value of the position is $712,965 USD.
View on StockTwits ↗
Stock_profit_03@Stock_profit_03Bullish9h
$GLSI Vanguard Portfolio Management Llc reports 37.26% increase in ownership of GLSI / Greenwich LifeSciences, Inc. On August 13, 2026 - Vanguard Portfolio Management Llc filed a 13F-HR form disclosing ownership of 80,861 shares of Greenwich LifeSciences, Inc. (US:GLSI) valued at $1,896,999 USD as of June 30, 2026. The entity filed a previous 13F-HR on May 8, 2026 disclosing 58,911 shares of Greenwich LifeSciences, Inc.. This represents a change in shares of 37.26% during the quarter. The current value of the position is $1,326,929 USD.
View on StockTwits ↗
Aura@ExploringTradesBullish13h
Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $GLSI PO
View on StockTwits ↗
Adam Muny@show_me_the_money_AdamBullish16h
$GP Waiting for a banger here. Any day now we get our big run. I want to bring more cash to $GLSI
View on StockTwits ↗
R.W.@Whiskeyunderthebed16h
$GLSI no volume today-dry. Should see a uptick into the close.
View on StockTwits ↗
Rolltide2020@Rolltide2020Bullish19h
$GLSI Even the worst possible buyout / partnership imaginable would be at least $500 million or $34 per share. This will not stay here long.
View on StockTwits ↗
Rolltide2020@Rolltide2020Bullish20h
$GLSI Fake drop. Going to finish green today.
View on StockTwits ↗
Rolltide2020@Rolltide2020Bullish21h
$GLSI Could get interesting today.
View on StockTwits ↗
Rolltide2020@Rolltide2020Bullish1d
$GLSI I love listening to older clips to see what I missed or what was said that came true. https://www.linkedin.com/posts/redchip_greenwich-lifesciences-ceo-on-advancing-activity-7491161222340464640-0qlW
View on StockTwits ↗
sheraz khan@WolfSK1d
$GLSI I have been buying up like crazy last 2 weeks. Seldom do you find a gem like this so undervalued. The biggest development for me is that FLAMINGO-01 is increasingly resembling a proper large pivotal breast-cancer study. Compared with the original relatively small trial, we’re now looking at a potentially up-to-2,000-patient, ~200-site, US/European, event-driven Phase III, enrolling across HLA types, with 28/56/133-event analyses and a design powered around HR 0.55. That’s much closer to the type of dataset a major oncology company would want to see behind a potentially important adjuvant therapy. The old trial potentially gave shareholders an answer sooner, but the new trial potentially gives GLSI a much stronger answer. If you are a large pharma considering paying serious money for the asset, you’d presumably rather see a robust multicentre pivotal programme than a tiny trial producing a dramatic but less convincing result. Partnership incoming??
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.